DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 14.96
(-1.45%)
CNY 14.96
(-1.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.17 Billion CNY | 1.65% |
| 2022 | 6.36 Billion CNY | 22.46% |
| 2021 | 5.19 Billion CNY | 24.89% |
| 2020 | 4.16 Billion CNY | 20.66% |
| 2019 | 3.44 Billion CNY | 16.93% |
| 2018 | 2.95 Billion CNY | 27.21% |
| 2017 | 2.31 Billion CNY | 21.55% |
| 2016 | 1.9 Billion CNY | 20.69% |
| 2015 | 1.58 Billion CNY | 14.78% |
| 2014 | 1.37 Billion CNY | 25.31% |
| 2013 | 1.09 Billion CNY | 18.79% |
| 2012 | 925.34 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.75 Billion CNY | -0.7% |
| 2024 Q1 | 1.76 Billion CNY | -14.78% |
| 2024 Q3 | 1.85 Billion CNY | 8.53% |
| 2023 Q4 | 2.07 Billion CNY | 25.76% |
| 2023 Q1 | 1.51 Billion CNY | -25.34% |
| 2023 Q2 | 1.63 Billion CNY | 7.72% |
| 2023 FY | 6.47 Billion CNY | 1.65% |
| 2023 Q3 | 1.64 Billion CNY | 1.09% |
| 2022 Q2 | 1.41 Billion CNY | 3.46% |
| 2022 FY | 6.36 Billion CNY | 22.46% |
| 2022 Q4 | 2.02 Billion CNY | 29.94% |
| 2022 Q3 | 1.56 Billion CNY | 10.42% |
| 2022 Q1 | 1.36 Billion CNY | -15.03% |
| 2021 Q1 | 1.11 Billion CNY | -13.85% |
| 2021 Q3 | 1.3 Billion CNY | 10.64% |
| 2021 FY | 5.19 Billion CNY | 24.89% |
| 2021 Q2 | 1.17 Billion CNY | 5.83% |
| 2021 Q4 | 1.6 Billion CNY | 23.42% |
| 2020 Q3 | 1.04 Billion CNY | 10.42% |
| 2020 Q2 | 942.74 Million CNY | 6.18% |
| 2020 FY | 4.16 Billion CNY | 20.66% |
| 2020 Q1 | 887.87 Million CNY | -12.81% |
| 2020 Q4 | 1.29 Billion CNY | 24.02% |
| 2019 FY | 3.44 Billion CNY | 16.93% |
| 2019 Q3 | 860.46 Million CNY | 7.18% |
| 2019 Q4 | 1.01 Billion CNY | 18.35% |
| 2019 Q1 | 768.35 Million CNY | -13.96% |
| 2019 Q2 | 802.8 Million CNY | 4.48% |
| 2018 Q1 | 623.65 Million CNY | -10.92% |
| 2018 Q4 | 893.05 Million CNY | 19.57% |
| 2018 FY | 2.95 Billion CNY | 27.21% |
| 2018 Q2 | 686.69 Million CNY | 10.11% |
| 2018 Q3 | 746.9 Million CNY | 8.77% |
| 2017 Q3 | 576.45 Million CNY | 6.92% |
| 2017 Q1 | 503.53 Million CNY | -13.08% |
| 2017 Q2 | 539.15 Million CNY | 7.08% |
| 2017 FY | 2.31 Billion CNY | 21.55% |
| 2017 Q4 | 700.13 Million CNY | 21.46% |
| 2016 Q2 | 446.09 Million CNY | 8.7% |
| 2016 Q1 | 410.4 Million CNY | 0.0% |
| 2016 Q3 | 472.3 Million CNY | 5.88% |
| 2016 Q4 | 579.3 Million CNY | 22.65% |
| 2016 FY | 1.9 Billion CNY | 20.69% |
| 2015 Q1 | 369.97 Million CNY | 0.0% |
| 2015 Q2 | 369.97 Million CNY | 0.0% |
| 2015 FY | 1.58 Billion CNY | 14.78% |
| 2014 FY | 1.37 Billion CNY | 25.31% |
| 2013 FY | 1.09 Billion CNY | 18.79% |
| 2012 FY | 925.34 Million CNY | 0.0% |